Cargando…

A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma

The distinction between follicular thyroid carcinomas (FTCs) and follicular-patterned benign lesions is almost impossible on fine-needle aspiration cytology. Furthermore, minimally invasive FTCs (MI-FTCs) with less than 4 vascular invasion foci generally have an excellent prognosis, but there are ex...

Descripción completa

Detalles Bibliográficos
Autores principales: Poma, Anello Marcello, Giannini, Riccardo, Piaggi, Paolo, Ugolini, Clara, Materazzi, Gabriele, Miccoli, Paolo, Vitti, Paolo, Basolo, Fulvio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754511/
https://www.ncbi.nlm.nih.gov/pubmed/29298844
http://dx.doi.org/10.1530/EC-17-0261
_version_ 1783290430889132032
author Poma, Anello Marcello
Giannini, Riccardo
Piaggi, Paolo
Ugolini, Clara
Materazzi, Gabriele
Miccoli, Paolo
Vitti, Paolo
Basolo, Fulvio
author_facet Poma, Anello Marcello
Giannini, Riccardo
Piaggi, Paolo
Ugolini, Clara
Materazzi, Gabriele
Miccoli, Paolo
Vitti, Paolo
Basolo, Fulvio
author_sort Poma, Anello Marcello
collection PubMed
description The distinction between follicular thyroid carcinomas (FTCs) and follicular-patterned benign lesions is almost impossible on fine-needle aspiration cytology. Furthermore, minimally invasive FTCs (MI-FTCs) with less than 4 vascular invasion foci generally have an excellent prognosis, but there are exceptions and, so far, no molecular marker appears able to identify them reliably. We aimed to distinguish benign lesions from low- and high-risk FTCs by a small-scale combination of genes. The expression analysis of 75 selected genes was performed on 18 follicular adenomas (FAs), 14 MI-FTCs and 6 widely invasive FTC (WI-FTCs). The mutational status of the RAS genes, TERT promoter and PAX8-PPARG rearrangements was also investigated. Seven samples were mutated, namely 3 MI-FTCs and 4 WI-FTCs. Twenty-five genes were differentially expressed (FDR <0.05) between FAs and WI-FTCs. Six of these (ECM1, RXRG, SDPR, SLC26A4, TIFF3, TIMP1) were also differently expressed among MI-FTCs and FAs or WI-FTCs and were considered to build a classification model, which was tested to classify samples according to their histological class. Hence, 31 out of 38 were correctly classified, and accuracy remained high after cross-validation (27/38). The 2 MI-FTCs incorrectly classified as WI-FTCs harbored both RAS and TERT promoter mutations. The capability of these six genes to stratify benign, low- and high-risk lesions appears to be promising in supporting the diagnosis of indeterminate thyroid nodules.
format Online
Article
Text
id pubmed-5754511
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Bioscientifica Ltd
record_format MEDLINE/PubMed
spelling pubmed-57545112018-01-09 A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma Poma, Anello Marcello Giannini, Riccardo Piaggi, Paolo Ugolini, Clara Materazzi, Gabriele Miccoli, Paolo Vitti, Paolo Basolo, Fulvio Endocr Connect Research The distinction between follicular thyroid carcinomas (FTCs) and follicular-patterned benign lesions is almost impossible on fine-needle aspiration cytology. Furthermore, minimally invasive FTCs (MI-FTCs) with less than 4 vascular invasion foci generally have an excellent prognosis, but there are exceptions and, so far, no molecular marker appears able to identify them reliably. We aimed to distinguish benign lesions from low- and high-risk FTCs by a small-scale combination of genes. The expression analysis of 75 selected genes was performed on 18 follicular adenomas (FAs), 14 MI-FTCs and 6 widely invasive FTC (WI-FTCs). The mutational status of the RAS genes, TERT promoter and PAX8-PPARG rearrangements was also investigated. Seven samples were mutated, namely 3 MI-FTCs and 4 WI-FTCs. Twenty-five genes were differentially expressed (FDR <0.05) between FAs and WI-FTCs. Six of these (ECM1, RXRG, SDPR, SLC26A4, TIFF3, TIMP1) were also differently expressed among MI-FTCs and FAs or WI-FTCs and were considered to build a classification model, which was tested to classify samples according to their histological class. Hence, 31 out of 38 were correctly classified, and accuracy remained high after cross-validation (27/38). The 2 MI-FTCs incorrectly classified as WI-FTCs harbored both RAS and TERT promoter mutations. The capability of these six genes to stratify benign, low- and high-risk lesions appears to be promising in supporting the diagnosis of indeterminate thyroid nodules. Bioscientifica Ltd 2017-11-27 /pmc/articles/PMC5754511/ /pubmed/29298844 http://dx.doi.org/10.1530/EC-17-0261 Text en © 2018 The authors http://creativecommons.org/licenses/by-nc/4.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Research
Poma, Anello Marcello
Giannini, Riccardo
Piaggi, Paolo
Ugolini, Clara
Materazzi, Gabriele
Miccoli, Paolo
Vitti, Paolo
Basolo, Fulvio
A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma
title A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma
title_full A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma
title_fullStr A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma
title_full_unstemmed A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma
title_short A six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma
title_sort six-gene panel to label follicular adenoma, low- and high-risk follicular thyroid carcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5754511/
https://www.ncbi.nlm.nih.gov/pubmed/29298844
http://dx.doi.org/10.1530/EC-17-0261
work_keys_str_mv AT pomaanellomarcello asixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT gianniniriccardo asixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT piaggipaolo asixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT ugoliniclara asixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT materazzigabriele asixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT miccolipaolo asixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT vittipaolo asixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT basolofulvio asixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT pomaanellomarcello sixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT gianniniriccardo sixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT piaggipaolo sixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT ugoliniclara sixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT materazzigabriele sixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT miccolipaolo sixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT vittipaolo sixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma
AT basolofulvio sixgenepaneltolabelfollicularadenomalowandhighriskfollicularthyroidcarcinoma